C12N 2760/20145
Special targeting system for viral vectors
C12N2760/20145 (Special targeting system for viral vectors) appears on 5 US grants and 8 published applications in this corpus.
Search patents in C12N- Granted patents
- 5
- Published applications
- 8
- Assignees
- 12
- Inventors
- 14
- Latest grant
- 3 Sep 2019
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 2 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 2 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 1 |
| 2017 | 1 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Identification of antibodies specific for lyssaviruses and methods of their use3 Sep 2019US 10,400,031 B2The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
- Identification of antibodies specific for at least two different lyssaviruses7 Nov 2017US 9,809,643 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Identification of antibodies specific for lyssaviruses and methods of their use25 Aug 2015US 9,115,187 B2The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
- Rhabdoviruses with reengineered coats25 Jul 2006US 7,081,243 B1Yale University
- Genetically engineered rabies recombinant vaccine for immunization of stray dogs and wildlife11 Jul 2006US 7,074,413 B2Thomas Jefferson University
- Arrdc1-mediated microvesicle-based delivery of therapeutic agents to cells of the peripheral nervous system27 Aug 2026US 2026/0248957 A1Turn Biotechnologies, Inc.
- Compositions of glycoprotein particles27 Jun 2024US 2024/0207196 A1Scribe Therapeutics Inc.
- Pseudotyped recombinant lyssaviruses for gene therapy13 Apr 2023US 2023/0110201 A1Beam Therapeutics Inc.
- Identification of antibodies specific for lyssaviruses and methods of their use17 May 2018US 2018/0134767 A1The Government of the U.S.A. as rep. by the Secretary of the Dept.of Health and Human Services
- Identification of antibodies specific for lyssaviruses and methods of their use28 Jan 2016US 2016/0024185 A1The Government of the United States of America as represented by the Secretary of the Department of
Most cited
By later US patents